Wall Street Zen lowered shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) from a hold rating to a sell rating in a research report released on Friday.
A number of other research firms also recently issued reports on TRVI. Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. HC Wainwright assumed coverage on shares of Trevi Therapeutics in a research report on Wednesday, May 28th. They set a "buy" rating and a $21.00 target price on the stock. B. Riley reiterated a "buy" rating and issued a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Finally, Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the company from $9.00 to $29.00 in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $18.63.
Check Out Our Latest Analysis on Trevi Therapeutics
Trevi Therapeutics Price Performance
Shares of Trevi Therapeutics stock traded down $0.65 during trading hours on Friday, hitting $6.41. The company had a trading volume of 2,577,968 shares, compared to its average volume of 1,331,942. The company's 50-day moving average is $6.26 and its two-hundred day moving average is $5.02. The company has a market cap of $640.31 million, a P/E ratio of -14.57 and a beta of 0.59. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.48.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.04. Sell-side analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.
Insider Transactions at Trevi Therapeutics
In other news, CEO Jennifer L. Good sold 5,263 shares of the firm's stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $1,403,599.54. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 18.30% of the company's stock.
Hedge Funds Weigh In On Trevi Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. Summit Investment Advisors Inc. boosted its position in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Trevi Therapeutics in the fourth quarter valued at $49,000. Strs Ohio acquired a new position in Trevi Therapeutics in the first quarter valued at $52,000. Squarepoint Ops LLC purchased a new stake in Trevi Therapeutics in the 4th quarter valued at about $58,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $66,000. 95.76% of the stock is owned by institutional investors and hedge funds.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
See Also
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
